{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T04:51:59Z","timestamp":1767934319345,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.cellimm.2017.12.013","type":"journal-article","created":{"date-parts":[[2017,12,30]],"date-time":"2017-12-30T02:37:58Z","timestamp":1514601478000},"page":"50-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["High macrophage PD-L1 expression not responsible for T cell suppression"],"prefix":"10.1016","volume":"324","author":[{"given":"Naomi","family":"Goldman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yelizavet D.","family":"Lomakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Londregan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Bucknum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelley","family":"DePierri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Somerville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Riggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2017.12.013_b0005","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nature20141","article-title":"Macrophages redirect phagocytosis by non-professional phagocytes and influence inflammation","volume":"539","author":"Han","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2017.12.013_b0010","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1600-065X.2008.00657.x","article-title":"Lymphoid stroma in the initiation and control of immune responses","volume":"224","author":"Mueller","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cellimm.2017.12.013_b0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases- elimination, equilibrium, and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.cellimm.2017.12.013_b0020","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/bjc.1988.36","article-title":"Macrophages in human breast disease: a quantitative immunohistochemical study","volume":"57","author":"Kelly","year":"1988","journal-title":"Br. J. Cancer."},{"key":"10.1016\/j.cellimm.2017.12.013_b0025","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockpoint in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cellimm.2017.12.013_b0030","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s12026-011-8262-6","article-title":"Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy","volume":"51","author":"Sato","year":"2011","journal-title":"Immunol. Res."},{"key":"10.1016\/j.cellimm.2017.12.013_b0035","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/bjc.2013.362","article-title":"Tumour-infiltration CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer","volume":"109","author":"Chaput","year":"2013","journal-title":"Br. J. Cancer."},{"key":"10.1016\/j.cellimm.2017.12.013_b0040","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.canlet.2016.04.038","article-title":"Tumor microenvironment: the culprit for ovarian cancer metastasis?","volume":"377","author":"Luo","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cellimm.2017.12.013_b0045","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.immuni.2016.02.025","article-title":"Integrative analysis of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability","volume":"44","author":"Mlecnik","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.cellimm.2017.12.013_b0050","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2017.12.013_b0055","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2017.12.013_b0060","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2017.12.013_b0065","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2017.12.013_b0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2016.11.007","article-title":"Resistance to PD1\/PDL1 checkpoint inhibition","volume":"52","author":"O\u2019Donnell","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.cellimm.2017.12.013_b0075","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2567.2005.02312.x","article-title":"Peritoneal macrophages suppress T-cell activation by amino acid catabolism","volume":"117","author":"Matlack","year":"2006","journal-title":"Immunology"},{"key":"10.1016\/j.cellimm.2017.12.013_b0080","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.imbio.2010.04.002","article-title":"Peritoneal T lymphocyte regulation by macrophages","volume":"216","author":"Composto","year":"2011","journal-title":"Immunobiology"},{"key":"10.1016\/j.cellimm.2017.12.013_b0085","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/cmi.2012.13","article-title":"CD28 ligation increases macrophage suppression of T-cell proliferation","volume":"9","author":"Silberman","year":"2012","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.cellimm.2017.12.013_b0090","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cellimm.2017.02.002","article-title":"Macrophage regulation of B cell proliferation","volume":"314","author":"Goldman","year":"2017","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.cellimm.2017.12.013_b0095","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2017.12.013_b0100","first-page":"4472","article-title":"T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression","volume":"7","author":"June","year":"1987","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.cellimm.2017.12.013_b0105","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cellimm.2017.12.013_b0110","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/ni0909-929","article-title":"From IL-10 to IL-12: how pathogens and their products stimulate APCs to induce T(H)1 development","volume":"10","author":"O\u2019Garra","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cellimm.2017.12.013_b0115","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2172-12-43","article-title":"Transition of tumor-associated macrophages from MHC class IIhi to MHC class IIlow mediates tumor progression in mice","volume":"12","author":"Wang","year":"2011","journal-title":"BMC Immunol."},{"key":"10.1016\/j.cellimm.2017.12.013_b0120","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2901","article-title":"The double life of a B-1 cell: self-reactivity selects for protective effector functions","volume":"11","author":"Baumgarth","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2017.12.013_b0125","doi-asserted-by":"crossref","unstructured":"A. Popi, l. Longo-Maugeri, M. Mariano, An overview of B-1 cells as antigen-presenting cells, Front. Immunol., 7 (2016) 138.","DOI":"10.3389\/fimmu.2016.00138"},{"key":"10.1016\/j.cellimm.2017.12.013_b0130","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.1038\/ncomms6997","article-title":"PD-L1hi B cells are critical regulators of humoral immunity","volume":"6","author":"Khan","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellimm.2017.12.013_b0135","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/ni.2705","article-title":"Tissue-resident macrophages","volume":"14","author":"Davies","year":"2014","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cellimm.2017.12.013_b0140","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.4049\/jimmunol.169.10.5538","article-title":"Expression of programmed death 1 ligands by murine T cells and APC","volume":"169","author":"Yamazaki","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2017.12.013_b0145","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2017.12.013_b0150","doi-asserted-by":"crossref","first-page":"564","DOI":"10.4049\/jimmunol.1401661","article-title":"Early development in the peritoneal cavity of CD49dhigh Th1 memory phenotype CD4+ T cells with enhanced B cell helper activity","volume":"195","author":"Moon","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2017.12.013_b0155","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.4049\/jimmunol.175.3.1586","article-title":"Blockade of B7\u2013H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-\u03b3-induced nitric oxide production","volume":"175","author":"Yamazaki","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2017.12.013_b0160","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/nm1554","article-title":"IFN-\u03b3 mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy","volume":"13","author":"Berner","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellimm.2017.12.013_b0165","doi-asserted-by":"crossref","first-page":"7898","DOI":"10.4049\/jimmunol.0901060","article-title":"Dual control of antitumor CD8 T cells through the programmed death-1\/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counter-regulation","volume":"183","author":"Currie","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2017.12.013_b0170","doi-asserted-by":"crossref","first-page":"e113840","DOI":"10.1371\/journal.pone.0113840","article-title":"Residual endotoxin contaminations in recombinant proteins are sufficient to activate human CD1c+ dendritic cells","volume":"9","author":"Schwarz","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cellimm.2017.12.013_b0175","doi-asserted-by":"crossref","unstructured":"K. Buscher, E. Ehinger, P. Gupta, A. Pramod, D. Wolf, G. Tweet, C. Pan, C. Mills, A. Lusis, K. Ley, Natural variation of macrophage activation as disease-relevant phenotype predictive of inflammation and cancer survival, Nat. Commun., Jul 24, 8 (2017) 16041.","DOI":"10.1038\/ncomms16041"},{"key":"10.1016\/j.cellimm.2017.12.013_b0180","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","article-title":"Combination cancer immunotherapy and new immunomodulatory targets","volume":"14","author":"Mahoney","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cellimm.2017.12.013_b0185","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrclinonc.2015.209","article-title":"Combination cancer immunotherapies tailored to the tumour microenvironment","volume":"13","author":"Smyth","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2017.12.013_b0190","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ni.3682","article-title":"\u2018Final common pathway\u2019 of human cancer immunotherapy: targeting random somatic mutations","volume":"18","author":"Tran","year":"2017","journal-title":"Nat. Immunol."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000887491730240X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000887491730240X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T22:56:28Z","timestamp":1757804188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000887491730240X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":38,"alternative-id":["S000887491730240X"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2017.12.013","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High macrophage PD-L1 expression not responsible for T cell suppression","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2017.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}